Chromosome analysis of nuclear power plant workers using fluorescence in situ hybridization and Giemsa assay

Abstract In situ technique for measuring radionuclides in the soil using a portable Ge detector is a highly versatile tool for both the radiological characterization and for the monitoring of operating nuclear power plants. The main disadvantage of this technique is related to the lack of knowledge of the geometry of the source whose activity concentration is to be determined. However, its greatest advantage is the high spatial representability of the samples and the lower time and resource consumption than gamma spectrometry lab measurements. In this study, the possibilities and limits offered by in situ gamma spectrometry with a high resolution gamma portable detector in two common uses are shown: First, the radiological background characterization and its relationship with the geology of an area of 2700 km2 are assessed; Secondly, its potential for monitoring man-made activity concentration in soils located around an operating nuclear power plant in Spain for surveillance purposes is evaluated. Finally, high accuracy radiation maps have been prepared from the measurements carried out. These radiation maps are essential tools to know the radioactive background of an area, especially useful to assess artificial radioactive deposits produced after a nuclear accident or incident.

Download Full-text

Multiplex Fluorescence In Situ Hybridization (M-FISH) in the Detection of Complex Karyotypic Abnormalities of Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Blood ◽

10.1182/blood.v106.11.4504.4504 ◽

2005 ◽

Vol 106 (11) ◽

pp. 4504-4504

Author(s):

Jianyong Li ◽

Jinlan Pan ◽

Bing Xiao ◽

Li Ma ◽

Hairong Qiu ◽

...

Keyword(s):

Acute Myeloid Leukemia ◽

In Situ Hybridization ◽

Fluorescence In Situ Hybridization ◽

Myelodysplastic Syndromes ◽

Myeloid Leukemia ◽

Chromosome Analysis ◽

Chromosome 17 ◽

Structural Aberrations ◽

Acute Myeloid

Abstract The complex chromosome abnormalities (CCAs) were one of the most important poor prognostic risk factors in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Chromosome analysis using classical cytogenetic banding techniques fails to completely resolve complex karyotypes and cryptic translocations. The technique of multiplex fluorescence in situ hybridization (M-FISH) allow for the simultaneous visualization of all chromosomes of a metaphase in a single hybridization step and thereby enable to comprehensively analyze complex karyotypes and the identification of new and cryptic translocations. To investigate the value of M-FISH in the detection of complex karyotypic abnormalities of AML and MDS. M-FISH was used in combination with interphase-FISH to study 24 cases of AML and MDS with CCAs showed by R-banding of conventional cytogenetics (CC). In 14 cases of AML with CCAs, 4 gains of whole chromosome and 4 losses of whole chromosome were confirmed by M-FISH, while 12 losses of whole chromosome were revised as derivative chromosomes resulted from various structural aberrations. 26 derivative chromosomes and 19 marker chromosomes were characterized precisely by M-FISH. Most of them were unbalanced translocations, including 2 complex t(8;21), which have not been previously described:t(8;21), der(8) t(8;21) (8pter→8q22::21q22→21qter), der(21) t(8;21;8) (8qter→ 8q22::21p13→ 21q22::8q22→ 8qter) and t(21;8;18;1), der(8) t(8;21) (8pter→ 8q22::21q22→ 21qter), der(21) t(21;8;18;1) (21p13→ 21q22::8q22→ 8q24::18?::1q?q?). In 10 cases of MDS, 37 kinds of structural rearrangements were detected by M-FISH including insertion, deletion, translocation and derivative chromosomes, and among them 34 kinds were unbalanced rearrangements, only 3 were balanced rearrangements including t(6;22)(q21;q12), t(9;19)(q13;p13) and t(3;5)( ?;?), 7 abnormalities were never reported before. The CCAs invloved nearly all chromosomes, of which the chromosome 17, 5 and 7 were invloved more frequent than the rest. Chromosomes 5, 17, 7 were involved in 15 cases (62.5%), 12 cases (50%) and 6 cases (25%) respecrively. We conclude that M-FISH could refine CCAs of AML and MDS patients, find or correct the missed or misidentified aberrations by CC analysis. Our findings confirm that M-FISH is a powerful tool to characterize complex karyotypes in AML and MDS.

Download Full-text

Room Classification Based on EMC Conditions in Nuclear Power Plants

Energies ◽

10.3390/en13020359 ◽

2020 ◽

Vol 13 (2) ◽

pp. 359 ◽

Cited By ~ 1

Author(s):

Hrvoje Grganić ◽

Davor Grgić ◽

Siniša Šadek

Keyword(s):

Power Plant ◽

Nuclear Power Plant ◽

Nuclear Power ◽

Power Plants ◽

Nuclear Power Plants ◽

Electromagnetic Compatibility ◽

Numerical Calculations ◽

Operational Experience ◽

Systematic Classification

Electromagnetic compatibility (EMC) in nuclear power plants today mostly relies on the qualification tests of the new equipment and adhering to some good installation practices. Diversity of the electromagnetic environment and different susceptibility of the plant equipment calls for a systematic classification of the EMC zones in a nuclear power plant. The paper proposes a methodology that uses a combination of the qualification tests, in situ and bench immunity tests, site survey measurements, operational experience, and numerical calculations to divide a nuclear power plant into a reasonable number of EMC zones. This would primarily help to have a better overview of the current EMC level in the plant and to unify emission and susceptibility requirements for the new equipment. In this paper, special attention is given to the preparation and performance of the in situ tests, which present the most challenging step of the methodology. In addition, the paper proposes some of the possible applications of the numerical calculations and addresses their challenges and limitations. The novel classification methodology, inspired by the equipment qualification program, is illustrated with examples from Krško Nuclear Power Plant, which recently performed a comprehensive EMC assessment.

Download Full-text

Cytogenetic and fluorescence in situ hybridization testing in veterans with chronic lymphocytic leukemia.

Journal of Clinical Oncology ◽

10.1200/jco.2017.35.15_suppl.7526 ◽

2017 ◽

Vol 35 (15_suppl) ◽

pp. 7526-7526 ◽

Cited By ~ 1

Author(s):

Ahmad Sami Halwani ◽

Zachary Burningham ◽

Kelli Marie Rasmussen ◽

Vikas Patil ◽

Clarke Alan Low ◽

...

Keyword(s):

In Situ Hybridization ◽

Chronic Lymphocytic Leukemia ◽

Fluorescence In Situ Hybridization ◽

Chromosome Analysis ◽

Lymphocytic Leukemia ◽

Novel Agents ◽

The Novel ◽

Entire Cohort ◽

Treatment Regimens

7526 Background: The presence of deletion 17p (del17), determined by chromosome analysis and/or fluorescence in situ hybridization (FISH), is a strong negative prognostic marker in chronic lymphocytic leukemia (CLL). Prior to the introduction of novel agents (ibrutinib, venetoclax), the clinical utility of cytogenetics/FISH was limited by the absence of chemoimmunotherapy regimens that were proven effective in patients with del17. Testing practices for chromosomal aberrations since the introduction of novel agents have not been reported. We report cytogenetic/FISH trends in a nationwide cohort of veterans diagnosed with CLL. Methods: CLL patients diagnosed 2008-2015 and receiving care at VA were identified through the VA Clinical Cancer Registry. Electronic medical records were used to determine cytogenetic/FISH testing (lab records), treatment histories (pharmacy dispensation records), and evidence of system use (heme-onc notes). Cytogenetic/FISH testing was identified by presence of specific keywords in the test name or Logical Observation Identifiers Names and Codes (LOINC) descriptions, then validated by human annotation. The testing rates are reported for the entire cohort, at time of diagnosis, time of regimen initiation (including the 12 months preceding initiation), during the novel era (2014 – 2015) and prior (2008–2013). Results: From 2008 to 2015, 3,638 CLL patients were diagnosed and received care at VA. Documented records of treatment regimens were available for 1,562 patients who received a total of 2,929 treatment regimens. Only 24% (998) of patients were tested at any point in time during their care at the VA, 17% (622) were tested at time of diagnosis, and 19% (542) of treatment courses were preceded by cytogenetic/FISH testing. No testing differences existed following the introduction of the novel agents at diagnosis (both ~ 17%), or prior to regimen initiation (20% vs 16%). Conclusions: Our study suggests CLL patients diagnosed and receiving care at the VA are not routinely undergoing cytogenetics/FISH testing at diagnosis or prior to treatment. Changing this practice pattern will personalize treatments so that del17 CLL patients receive less toxic and more effective therapies.

Download Full-text